Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial

Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.  

Heads
Blinded double-dummy head-to-head studies may be key to driving change in the IBD marketplace • Source: Shutterstock

Preliminary clinical data showing Takeda Pharmaceutical Co. Ltd.’s gut-selective biologic, vedolizumab (Entyvio), was superior to AbbVie Inc.’s anti-TNF biologic Humira (adalimumab) in achieving clinical remissions in patients with moderate-to-severe active ulcerative colitis could have important implications for clinical practice, and also commercially for the therapeutic sector.

The VARSITY study is thought to be one of the first head-to-head blinded comparisons of two biologics in inflammatory bowel...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category